{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:34:31Z","timestamp":1793604871833,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Compared to estimated population prevalence rates, relatively few patients at risk are diagnosed with and treated for transthyretin cardiac amyloidosis (ATTR-CA). Where along the clinical pathway patient drop-off occurs, as well as the association of drop-off with patient sociodemographic characteristics, remains unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using data from a healthcare system\u2013wide cardiovascular imaging repository and specialty pharmacy, we characterized the clinical pathway from diagnosis with pyrophosphate scintigraphy (PYP) to tafamidis prescription, initiation, and adherence. Standardized differences (d values of \u22650.20, indicating at least a small effect size) were used to compare sociodemographics (age, sex, race, Area Deprivation Index) among patients with PYP-identified ATTR-CA by tafamidis prescription status and among patients prescribed tafamidis by initiation status. Tafamidis adherence was measured with the proportion of days covered (PDC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 97 patients with ATTR-CA, 58.8% were prescribed tafamidis, with 80.7% of those initiating therapy. Patients with ATTR-CA prescribed tafamidis were younger than those not prescribed tafamidis (d = \u20130.30). Utilization of a specialty pharmacy resulted in enrichment of treatment in subgroups traditionally undertreated in cardiovascular medicine, with higher rates of tafamidis initiation among women (100% initiation), patients of Black\/African American race (d = 0.40), and those living in more economically disadvantaged areas (d \u2265 0.30). Adherence was high (PDC of &amp;gt;80%) in 88.4% of those initiating tafamidis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings highlight the tremendous opportunity for more robust ATTR-CA clinical programs, identifying potential patient subgroups that should be targeted to reduce disparities. For patients diagnosed with ATTR-CA, utilization of a specialty pharmacy process appears to ensure equitable provision of tafamidis therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae183","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:58:45Z","timestamp":1720115925000},"page":"1245-1251","source":"Crossref","is-referenced-by-count":5,"title":["From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics"],"prefix":"10.1093","volume":"81","author":[{"given":"Kristie M","family":"Walenczyk","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT"},{"name":"Department of Psychology, VA Connecticut Healthcare System , West Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinainder","family":"Singh","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimhouy","family":"Tong","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Services, Yale New Haven Health , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M","family":"Burg","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT"},{"name":"Department of Cardiology, VA Connecticut Healthcare System , West Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Miller","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"22","key":"2024121018582408300_CIT0001","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2024121018582408300_CIT0002","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"2024121018582408300_CIT0003","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","article-title":"Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis","volume":"24","author":"Papoutsidakis","year":"2018","journal-title":"J Card Fail"},{"issue":"9","key":"2024121018582408300_CIT0004","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"38","key":"2024121018582408300_CIT0005","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"2024121018582408300_CIT0006","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2024121018582408300_CIT0007","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"2024121018582408300_CIT0008","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"issue":"10","key":"2024121018582408300_CIT0009","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"2024121018582408300_CIT0010","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"11","key":"2024121018582408300_CIT0011","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2024121018582408300_CIT0012","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ehjqcco\/qcab031","article-title":"Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies","volume":"8","author":"Rozenbaum","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2024121018582408300_CIT0013","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol"},{"issue":"3","key":"2024121018582408300_CIT0014","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","article-title":"Tafamidis\u2014a pricey therapy for a not-so-rare condition","volume":"5","author":"Gurwitz","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"15","key":"2024121018582408300_CIT0015","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"2024121018582408300_CIT0016","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jamacardio.2020.0863","article-title":"Initial monthly cost of tafamidis\u2014the real price for patients","volume":"5","author":"Cuddy","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"9","key":"2024121018582408300_CIT0017","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"13","key":"2024121018582408300_CIT0018","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ajhp\/zxad064","article-title":"2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services","volume":"80","author":"Zuckerman","year":"2023","journal-title":"Am J Health-Syst Pharm"},{"issue":"7","key":"2024121018582408300_CIT0019","doi-asserted-by":"publisher","first-page":"766","DOI":"10.18553\/jmcp.2022.28.7.766","article-title":"Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and\/or receiving tafamidis prescriptions: a retrospective analysis of a Medicare cohort","volume":"28","author":"Roy","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2024121018582408300_CIT0020","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/PPA.S352332","article-title":"Baseline characteristics and secondary medication adherence patterns among patients receiving tafamidis prescriptions: a retrospective analysis using a national specialty pharmacy dispensing database","volume":"16","author":"Roy","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"22","key":"2024121018582408300_CIT0021","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"2024121018582408300_CIT0022","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/acem.13371","article-title":"Sex differences in diagnoses, treatment, and outcomes for emergency department patients with chest pain and elevated cardiac troponin","volume":"25","author":"Humphries","year":"2018","journal-title":"Acad Emerg Med"},{"issue":"suppl 3","key":"2024121018582408300_CIT0023","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/ s11606-022-07595-1","article-title":"Gender differences in guideline-directed medical therapy for cardiovascular disease among young veterans","volume":"37","author":"Dhruva","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2024121018582408300_CIT0024","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s40615-021-00984-y","article-title":"Prevalence of guideline-directed medical therapy for cardiovascular disease among Baltimore City adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) study","volume":"9","author":"Mathews","year":"2022","journal-title":"J Racial Ethn Health Disparities"},{"key":"2024121018582408300_CIT0025","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2458-8-44","article-title":"The association between socioeconomic position, use of revascularization procedures and five-year survival after recovery from acute myocardial infarction","volume":"8","author":"Rosvall","year":"2008","journal-title":"BMC Public Health"},{"key":"2024121018582408300_CIT0026","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ijcard.2017.02.070","article-title":"Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival","volume":"235","author":"Akita","year":"2017","journal-title":"Int J Cardiol"},{"issue":"4","key":"2024121018582408300_CIT0027","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/eurheartj\/ehn539","article-title":"Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II","volume":"30","author":"Komajda","year":"2009","journal-title":"Eur Heart J"},{"issue":"26","key":"2024121018582408300_CIT0028","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood disadvantage metrics accessible: the Neighborhood Atlas","volume":"378","author":"Kind","year":"2018","journal-title":"N Engl J Med"},{"key":"2024121018582408300_CIT0029","author":"University of Wisconsin School of Medicine and Public Health","year":"2015"},{"issue":"7","key":"2024121018582408300_CIT0030","doi-asserted-by":"publisher","first-page":"e000030","DOI":"10.1161\/HCI.0000000000000030","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/ SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2\u2014diagnostic criteria and appropriate utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024121018582408300_CIT0031","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"key":"2024121018582408300_CIT0032","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"1","key":"2024121018582408300_CIT0033","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","article-title":"Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study","volume":"12","author":"Garcia-Pavia","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2024121018582408300_CIT0034","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.1378","article-title":"Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure","volume":"106","author":"Ihle","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2024121018582408300_CIT0035","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae183\/58575493\/zxae183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/24\/1245\/60956198\/zxae183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/24\/1245\/60956198\/zxae183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:56:48Z","timestamp":1733860608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/24\/1245\/7706160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,7,4]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae183","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,15]]},"published":{"date-parts":[[2024,7,4]]}}}